| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Traumatic Acid does not have a classical pharmacological target in mammals. It is a plant hormone (cytokinin) that promotes wound healing by stimulating cell division at trauma sites. In mammalian systems, it enhances collagen biosynthesis in cultured human skin fibroblasts and inhibits the survival of MCF-7 breast cancer cells by enhancing apoptosis and oxidative stress.
|
|---|---|
| ln Vitro |
Fibroblast cell count is dramatically increased by wound acid (0.1, 1 µM; 5 days) [1]. In fibroblasts, traumatic acid (0.1, 1 µM; 5 days) decreases glutathione level, increases GPX activity, and lessens membrane phospholipid peroxidation [1]. In fibroblast culture media, traumatizing acid (0.1, 1 µM; 5 days) increases collagen secretion and synthesis [1]. The number of viable cells was dramatically decreased by wound acid (100, 200, 400, and 600 µM; 48 hours), particularly following treatment at 100 µM and 200 µM for 48 hours in MCF-7 cells [2]. In MCF-7 cells, traumatic acid (50–600 µM; 24–48 hours) promotes apoptosis and reduces cell viability in a dose- and time-dependent manner [2]. In MCF-7 cells, traumatic acid (50–200 µM; 24–48 hours) oxidatively damages proteins [2]. The oxidative stress level of MCF-7 cells can be efficiently increased by traumatic acid (100, 200 µM; 24, 48 hours) [2].
In vitro, Traumatic Acid enhances collagen biosynthesis in cultured human skin fibroblasts. It inhibits the survival rate of MCF-7 breast cancer cells and enhances apoptosis and oxidative stress. The compound also functions as a wound healing agent in plants, stimulating cell division to form a protective callus. |
| ln Vivo |
In vivo, Traumatic Acid has been studied for its effects on tissue repair and wound healing. It may offer therapeutic benefits in treating inflammatory conditions, skin injuries, and certain autoimmune disorders. Topical application of trans-traumatic acid has been shown to have important effects on the healing and closure of diabetic wounds in a streptozotocin-induced diabetic mouse model.
|
| Enzyme Assay |
In vitro assays for Traumatic Acid typically involve measuring its effects on cell proliferation and collagen synthesis. Human skin fibroblasts are cultured and treated with the compound at various concentrations. Collagen biosynthesis is measured by ELISA or by incorporating radiolabeled proline. Cell viability is assessed by MTT or standard assays. Apoptosis is evaluated by Annexin V/PI staining and caspase-3/7 activity assays.
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Fibroblasts Tested Concentrations: 0.1, 1 µM Incubation Duration: 5 days Experimental Results: Caused a significant increase in cell number, especially on day 1 at a concentration of 1 µM. Compared to untreated control cells, cell numbers increased by 133% and 118% at concentrations of 1 and 0.1 µM, respectively. Cell viability assay[1] Cell Types: Fibroblasts Tested Concentrations: 0.1, 1 µM Incubation Duration: 5 days Experimental Results: Total protein content increased by 183% and 90% on day 1 compared to controls at concentrations of 1 and 0.1 µM, respectively . Collagen increased compared to control by 72% at 0.1 µM (day 3) and 51% at 1 µM (day 1). Compared to the control, GPX activity increased by 111% and 97% at concentrations of 1 and 0.1 µM, respectively. The diminished glutathione content increased by 86% and 80% at 0.1 µM and 1 µM, respectively. Reduce membrane phospholipid peroxidation. Cell viability assay [2] Cell Types: MCF-7 Cell Tested Concentrations: 100, 200, 400, 600 µM Incubation Duration: 4 For in vitro cell-based assays, MCF-7 breast cancer cells are cultured and treated with Traumatic Acid at various concentrations. Cell viability is assessed by MTT or standard assays. Apoptosis is evaluated by Annexin V/PI staining, caspase-3/7 activity assays, and oxidative stress markers. The compound's effects on collagen synthesis can be assessed in fibroblast cultures. |
| Animal Protocol |
In vivo animal studies with Traumatic Acid are conducted in models of wound healing, particularly diabetic wound healing. Topical application of trans-traumatic acid in a streptozotocin-induced diabetic mouse model promotes wound closure. The compound's effects on tissue repair and inflammation are assessed by measuring wound size, histopathological analysis, and inflammatory markers.
|
| ADME/Pharmacokinetics |
Traumatic Acid (CAS: 6402-36-4) has a molecular weight of 228.28 g/mol and a molecular formula of C12H20O4. IUPAC name: (E)-dodec-2-enedioic acid. Appearance: solid. Melting point: 192-195°C. Storage: room temperature. The compound is a naturally occurring wound healing agent and phytohormone.
|
| Toxicity/Toxicokinetics |
Traumatic Acid is a naturally occurring compound and is considered to have a low toxicity profile. It is used as a research compound and is not intended for human therapeutic use. In preclinical studies, it has shown potential for wound healing and anti-cancer applications. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Wound healing acid is a monounsaturated straight-chain dicarboxylic acid with a double bond located at the C-2 position; it is a plant wound healing hormone and functions as a plant hormone. Wound healing acid has been reported in Meehania urticifolia, and relevant data are available for reference.
Traumatic Acid (trans-2-dodecenedioic acid) is a naturally occurring monounsaturated dicarboxylic acid that functions as a wound healing agent and cytokinin (phytohormone). It enhances collagen biosynthesis in human skin fibroblasts and inhibits MCF-7 breast cancer cell survival. It has a molecular weight of 228.28 g/mol and a molecular formula of C12H20O4. It is not FDA-approved and is intended for research use only. |
| Molecular Formula |
C12H20O4
|
|---|---|
| Molecular Weight |
228.2848
|
| Exact Mass |
228.136
|
| CAS # |
6402-36-4
|
| PubChem CID |
5283028
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
376.4±15.0 °C at 760 mmHg
|
| Melting Point |
165-167 °C(lit.)
|
| Flash Point |
195.6±16.9 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.493
|
| LogP |
2.95
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
16
|
| Complexity |
233
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CCCCC(=O)O)CCC/C=C/C(=O)O
|
| InChi Key |
MAZWDMBCPDUFDJ-VQHVLOKHSA-N
|
| InChi Code |
InChI=1S/C12H20O4/c13-11(14)9-7-5-3-1-2-4-6-8-10-12(15)16/h7,9H,1-6,8,10H2,(H,13,14)(H,15,16)/b9-7+
|
| Chemical Name |
(E)-dodec-2-enedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1095.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (9.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3806 mL | 21.9029 mL | 43.8059 mL | |
| 5 mM | 0.8761 mL | 4.3806 mL | 8.7612 mL | |
| 10 mM | 0.4381 mL | 2.1903 mL | 4.3806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
